Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Sex Transm Infect ; 94(4): 293-297, 2018 06.
Article in English | MEDLINE | ID: mdl-29066627

ABSTRACT

OBJECTIVES: Screening of men who have sex with men (MSM) for Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) requires sampling from anorectal and pharyngeal sites in addition to urogenital sampling. Due to the cost of testing multiple anatomical sites individually testing of pooled specimens has potential merit. The Cepheid GeneXpert CT/NG assay (GeneXpert), which also has potential for point-of-care nucleic acid testing in the sexual health clinic, has not been assessed for pooled specimen testing. METHODS: We prospectively compared GeneXpert testing of pooled pharyngeal and rectal swabs with urine samples to standard of care testing of individual specimens from 107 participants using the Roche cobas 4800 CT/NG assay (cobas) for CT and NG in high-risk MSM attending an inner city sexual health clinic. RESULTS: We found testing of pooled pharyngeal, rectal and urine samples by the GeneXpert to have 100% agreement for NG and 94% overall agreement for CT when compared with individual specimen testing by cobas. For CT testing, 14 cases were detected for both tests, 4for cobas only, 2 for GeneXpert only and 89 participants were negative for both tests. CONCLUSIONS: Pooled specimen CT and NG testing by the GeneXpert was accurate when compared with single specimen testing and has potential for screening MSM for CT and NG. The role of pooled specimen testing with the GeneXpert as a point-of-care nucleic acid test in MSM requires further investigation.


Subject(s)
Chlamydia Infections/diagnosis , Gonorrhea/diagnosis , Homosexuality, Male/statistics & numerical data , Pharyngeal Diseases/diagnosis , Rectal Diseases/diagnosis , Adolescent , Adult , Aged , Chlamydia Infections/urine , Chlamydia trachomatis/isolation & purification , Gonorrhea/urine , Humans , Male , Middle Aged , Neisseria gonorrhoeae/isolation & purification , Nucleic Acid Amplification Techniques/methods , Pharyngeal Diseases/microbiology , Pharyngeal Diseases/urine , Prospective Studies , Rectal Diseases/microbiology , Rectal Diseases/urine , Specimen Handling/methods , Young Adult
2.
Br J Surg ; 77(10): 1091-4, 1990 Oct.
Article in English | MEDLINE | ID: mdl-2224454

ABSTRACT

Procoagulant activity (PCA) in normal urine has been recognized for over 50 years. Although tissue factor (TF) is produced by certain tumours, and is increased in both tumour-associated macrophages and blood monocytes, the possibility that it might also be increased in urine has not been studied in patients with cancer. We have measured urinary PCA in hospital controls without inflammatory or neoplastic disease (n = 79), in patients with rheumatoid arthritis (n = 8), inflammatory bowel disease (n = 19), colorectal cancer (n = 70) and in patients undergoing colonoscopy (n = 50). Urinary PCA was higher (P less than 0.001) in patients with colorectal cancer and inflammatory bowel disease than controls or patients with rheumatoid arthritis. Fourteen (88 per cent) out of 16 colonoscopy patients subsequently found to have carcinoma or inflammatory bowel disease had levels above the control upper quartile, compared with 8 (24 per cent) out of 34 with normal colonoscopy (P less than 0.001). TF inhibitors confirmed the nature of the PCA and Western blotting studies indicated a urinary TF molecular weight of approximately 38,000. These studies provide further evidence of abnormal haemostasis in malignancy and suggest that determination of urinary TF may provide a useful screening test in patients undergoing colonoscopy.


Subject(s)
Colonic Diseases/urine , Rectal Diseases/urine , Thromboplastin/urine , Arthritis, Rheumatoid/urine , Blotting, Western , Colonoscopy , Colorectal Neoplasms/urine , Humans , Molecular Weight , Proctocolitis/urine , Thromboplastin/analysis , Thromboplastin/chemistry
SELECTION OF CITATIONS
SEARCH DETAIL
...